

NeuroBioTec Biobank – Hospices Civils de Lyon

<https://www.neurodegenerationresearch.eu/survey/neurobiotec-biobank-hospices-civils-de-lyon/>

Name of bioresource/bank

NeuroBioTec Biobank – Hospices Civils de Lyon

Name of Principal Investigator

Title Professor

First name CONFAVREUX

Last name CHRISTIAN

Address of institution where award is held

Institution Hopital Neurologique, Hospices Civils de Lyon

Street Address 59, Boulevard Pinel

City Lyon

Postcode 69677

Country

France

Website

www.neurobiotec.net

Contact email (e.g. manager or coordinator)

Funding source

Hospices Civils de Lyon

Q1 What conditions does your resource cover?

Alzheimer's disease and other dementias

Parkinson's disease

Neurodegenerative disease in general

Q2a What DNA collection does your resources hold?

101-1000 donors

Q2b What cell lines does your resource hold?

None

Q2c What tissue (including post-mortem tissue) does your resource hold?

101-1000 donors

Q3 Are human tissues/samples/DNA from

Living donors: blood

Living donors: blood derivatives

Living donors: DNA

Living donors: peripheral nerve biopsy

Living donors: skeletal muscle biopsy

Living donors: cerebro-spinal fluid

Q4 Are tissues/samples/DNA from

Healthy individuals/control donors

Patients

Q5 Can samples be linked to clinical (phenotypic) information and if so, is this information:

Routinely collected as medical records

In a specific study-associated dataset

Q6 In what form are samples supplied?

Primary Samples: Stabilised samples (frozen or fixed)

Secondary samples: plasma

Secondary samples: DNA

Q7 Are biomarkers/analytes/biological characteristics already measured and the information available for your samples?

In a few samples

Q8 What is the status of your tissue/sample/DNA collection?

Collection completed and available for use

Q9 What are the rules and procedures for access?

Access independent of collaboration with PI

Access Committee mechanism

International access

Access to industry

Resource has own ethics approval so usually no need for separate external ethics approval